Скачать или смотреть Webinar: Lung Cancer Clinical Trials Evaluating Efficacy and Overcoming Resistance | Veeda

Welcome to a compelling webinar on targeted therapies and lung cancer clinical trials, exploring their effectiveness and approaches to overcoming resistance. Presented by Veeda Clinical Research, a leader in clinical, pre-clinical, and bio-analytical services, this session delves into the world of innovative biosimilars and generic drug development programs for global clients.

The webinar discusses the shift from non-specific chemotherapy to targeted therapies in lung cancer treatment. These modern therapies focus on specific receptors or genes responsible for rapid cancer cell growth, thereby minimizing damage to healthy cells and reducing side effects.

Lung cancer remains a major global health concern, and the majority of cases fall into the non-small cell lung cancer (NSCLC) category. NSCLC patients often have genetic alterations, making targeted therapies an exciting avenue for treatment.

Specifically, drugs targeting epidermal growth factor receptors (EGFR) have shown significant promise. By identifying genetic abnormalities through biomarker testing, healthcare providers can tailor treatments and achieve better outcomes for patients.

Key highlights of this webinar: 
· Overview of Targeted therapies used in Lung Cancer
· Exploring the Key Endpoints such as Response Rate, Progression-free Survival, and Overall Survival 
· Challenges due to resistance to Targeted Therapies in Lung Cancer 
· Operational aspects related to the execution of Clinical Trials in Lung Cancer

The webinar delves into various approved therapies for lung cancer, including EGFR inhibitors, RLK inhibitors, ROS1 inhibitors, Braff inhibitors, and Met inhibitors.
The administration of TKIs as a first-line treatment for certain NSCLC mutations has demonstrated superior response rates, progression-free survival, and overall survival compared to traditional chemotherapy.

EGFR inhibitors, such as Pente-Mumab and Situk-Zimab, act by blocking cellular proliferation and survival pathways and have shown promise in improving efficacy. Meanwhile, anaplastic lymphocytic lymphoma kinase (ALK) mutations have also been identified as a potential target for lung cancer therapy.

Learn more about the remarkable world of targeted therapies in lung cancer and the exciting potential they hold in transforming patient outcomes. Don't miss this insightful and informative webinar, which aims to create awareness and foster collaboration in the field of cancer research and treatment.

Visit our website ➦ https://veedalifesciences.com/

If you like this video, do not forget to thumbs up, comment, and share this video.

Get notified of our new videos, click subscribe, and press the bell icon.    / @veedacr  

➦ Get social with us:
◉ Facebook:   / veedacr  
◉ Instagram:   / veedacr  
◉ Twitter:   / veedacr  
◉ LinkedIn:   / veedacr  
◉ Youtube:    / @veedacr  

➦ Tags and Keywords:
#LungCancer
#TargetedTherapies
#ClinicalTrials
#CancerResearch
#BiomarkerTesting
#EGFRInhibitors
#NSCLC
#TKIs
#MedicalResearch
#HealthcareWebinar
#CancerTreatment
#BiomedicalScience
#Oncology
#MedicalAdvancements
#PatientOutcomes
#Pharmacology
#Biosimilars
#GenericDrugDevelopment
#PrecisionMedicine
#HealthAwareness
#Veeda
#Veedalifesciences